非酒精性脂肪肝对药动学影响研究进展

Advances of the influence of nonalcoholic fatty liver disease on the pharmacokinetics

非酒精性脂肪肝(NAFLD)是一种最常见的慢性肝病,严重威胁人类健康。在影响药物代谢的各种因素中,慢性肝病所起的作用最重要,可导致肝脏基因表达、mRNA及蛋白表达改变。非酒精性脂肪肝动物模型和非酒精性脂肪肝炎患者的研究结果显示,非酒精性脂肪肝时药物代谢酶及药物转运体发生显著改变。药物代谢酶和药物转运体在药物代谢过程中发挥重要作用,其改变可能影响药物在体内的清除,导致诸多临床药物的疗效、毒副作用甚至药物相互作用的发生。随着非酒精性脂肪肝的流行,越来越多的药物用于非酒精性脂肪肝患者。因此本文就非酒精性脂肪肝对药动学影响的研究进展作一综述。

Nonalcoholic fatty liver disease （NAFLD） is one most common chronic liver disease, and it is a big threat against people＇s health. Chronic liver disease is the most impor- tant causes of effects on drug disposition, and it may lead to changes of gene, mRNA and protein expression. The results of NAFLD animal mod- els and NAFLD patients show that drug meta- bolic enzymes and transporters significantly change in NAFLD. Drug metabolic enzymes and transporters play important roles in drug dispo- sition,and lead to consequences for interindivid ual differences in disposition kinetics, interaction profiles of clinical drugs, susceptibility to side effects and treatment efficacy. With the prevalence of NAFLD, NAFLD patients have to take more and more drugs. So this review focuses on the influence of nonalcoholic fatty liver dis- ease on the pharmacokinetics.